

| Authors (GSID authors in Bold) | Title | Publication | Year | Field | GSID Author | Authors - Short | | |
|--|---|---|------|---------------|----------------|-----------------|--|--|
| Zhanna Shubin , Sherry Stanfield-Oakley , Jiraporn Puangkaew , Punnee Pitisutthithum , Sorachai Nitayaphan , Sanjay Gurunathan , Faruk Sinangil , Suwat Chariyalertsak , Nittaya Phanuphak , Julie A Ake , Robert J O'Connell , Sandhya Vasana , Siriwat Akapirat , Michael A Eller , Guido Ferrari , Dominic Paquin-Proulx ; for the RV306 Study Group | Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability | AIDS. 2023 Aug 1;37(10):1519-1524. https://journals.lww.com/aidsonline/fulltext/2023/08010/additional_boosting_to_the_rv144_vaccine_regimen.4.aspx | 2023 | HIV | Faruk Sinangil | Shubin et al | | |
| Margaret C. Costanzo, Dominic Paquin-Proulx, Alexandra Schuetz, Siriwat Akapirat, Zhanna Shubin, Dohoon Kim, Lindsay Wiecek, Victoria R. Polonis, Hung V. Trinh, Mangala Rao, Hanna Anenia, Michael D. Barrera, Jacob Boeckelman, Barbara Nails, Pallavi Thapa, Michelle Zemil, Carlo Sacdalan, Eugene Kroon, Boot Kaewboon, Somporn Tipsuk, Surat Jongrakthaitae, Sanjay Gurunathan, Faruk Sinangil , Jerome H. Kim, Merlin L. Robb, Julie A. Ake, Robert J. O'Connell, Punnee Pitisutthithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Michael A. Eller, Nittaya Phanuphak, Sandhya Vasana, the RV306, and RV328 study groups | ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone | JCI Insight. 2023;8(9):e167664. https://insight.jci.org/articles/view/167664 | 2023 | HIV | Faruk Sinangil | Costanzo et al | | |
| Giovanna Meza, Fátima Galián, Claudia Jaimes-Bernal, Francisco J Márquez, Faruk Sinangil , Carolina Scagnolari, Luis Miguel Real , Donald Forthal, Antonio Caruz | IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men | Virulence, 2022 Dec;13(1):757-763. https://doi.org/10.1080/21505594.2022.2066612 | 2022 | HIV | Faruk Sinangil | Meza et al | | |
| Manuela Sironi, Rachele Cagliani, Mara Biasin, Sergio Lo Caputo, Irma Saulle, Diego Forni, Luis Miguel Real, Juan Antonio Pineda, Almudena Exposito, María Eugenia Saez, Faruk Sinangil , Donald Forthal, Antonio Caruz and Mario Clerici | No association of a risk variant for severe COVID-19 with HIV protection in three cohorts of highly exposed individuals | PNAS Nexus, 2022, 1, 1–4 https://doi.org/10.1093/pnasnexus/pgac138 | 2022 | HIV, COVID-19 | Faruk Sinangil | Sironi et al | | |

| | | | | | | | | |
|--|--|---|-------------|------------|---|----------------------------|--|--|
| <p>Yunda Huang, Kelly E. Seaton, Martin Casapia, Laura Polakowski, Stephen C. De Rosa, Kristen Cohen, Chenchen Yu, Marnie Elizaga, Carmen Paez, Maurine D. Miner, Colleen F. Kelley, Janine Maenza, Michael Keefer, Javier R. Lama, Magdalena Sobieszczyk, Susan Buchbinder, Lindsey R. Baden, Carter Lee, Vineeta Gulati, Faruk Sinangil, David Montefiori, M. Juliana McElrath, Georgia D.Tomas, Harriet L. Robinson, Paul Goepfert, on behalf of the NIAID-funded HIV Vaccine Trials Network (HVTN) 114 Study Team</p> | <p>AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period</p> | <p>Vaccine, Volume 39, Issue 33, 30 July 2021, Pages 4641-4650, doi.org/10.1016/j.vaccine.2021.06.066</p> | <p>2021</p> | <p>HIV</p> | <p>Carter Lee, Vineeta Gulati, Faruk Sinangil</p> | <p>Huang et al</p> | | |
| <p>Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Dawson P, Dhitavat J, Phonrat B, Akapirat S, Karasavvas N, Wieczorek L, Polonis V, Eller MA, Pegu P, Kim D, Schuetz A, Jongrakthaitae S, Zhou Y, Sinangil F, Phogat S, Diazgranados CA, Tartaglia J, Heger E, Smith K, Michael NL, Excler JL, Robb ML, Kim JH, O'Connell RJ, Vasan S; RV306 study group.</p> | <p>Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.</p> | <p>Lancet HIV. 2020 Feb 6. pii: S2352-3018(19)30406-0. doi: 10.1016/S2352-3018(19)30406-0.</p> | <p>2020</p> | <p>HIV</p> | <p>Faruk Sinangil</p> | <p>Pitisuttithum et al</p> | | |
| <p>Easterhoff D, Pollara J, Luo K, Tolbert WD, Young B, Mielke D, Jha S, O'Connell RJ, Vasan S, Kim J, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Wiehe K, Saunders KO, Montefiori DC, Tomas GD, Moody MA, Pazgier M, Haynes BF, Ferrari G.</p> | <p>Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.</p> | <p>J Virol. 2020 Jan 31;94(4). pii: e01120-19. doi: 10.1128/JVI.01120-19.</p> | <p>2020</p> | <p>HIV</p> | <p>Faruk Sinangil</p> | <p>Easterhoff et al</p> | | |
| <p>Easterhoff D, Pollara J, Luo K, Janus B, Gohain N, Williams LD, Tay MZ, Monroe A, Peachman K, Choe M, Min S, Lusso P, Zhang P, Go EP, Desaire H, Bonsignori M, Hwang KK, Beck C, Kakalis M, O'Connell RJ, Vasan S, Kim JH, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Wiehe K, Saunders KO, Montefiori DC, Tomas GD, Moody MA, Arthos J, Rao M, Joyce MG, Ofek G, Ferrari G, Haynes BF.</p> | <p>HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.</p> | <p>JCI Insight. 2020 Jan 30;5(2). pii: 131437. doi: 10.1172/jci.insight.131437.</p> | <p>2020</p> | <p>HIV</p> | <p>Faruk Sinangil</p> | <p>Easterhoff et al</p> | | |

| | | | | | | | | |
|---|--|---|------|-----|-------------------------------|----------------|--|--|
| Meza G, Expósito A, Royo JL, Ruiz-García C, Sánchez-Arcas B, Marquez FJ, Gómez-Vidal MA, Omar M, Sinangil F, Higgins K , Forthal D, Real LM, Caruz A. | Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. | AIDS. 2020 Jan 1;34(1):25-32. doi: 10.1097/QAD.0000000000002401 | 2020 | HIV | Faruk Sinangil, Keith Higgins | Meza et al | | |
| Rouphael NG, Morgan C, Li SS, Jensen R, Sanchez B, Karuna S, Swann E, Sobieszczyk ME, Frank I, Wilson GJ, Tieu HV, Maenza J, Norwood A, Kobie J, Sinangil F , Pantaleo G, Ding S, McElrath MJ, De Rosa SC, Montefiori DC, Ferrari G, Tomaras GD, Keefer MC; HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network. | DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. | J Clin Invest. 2019 Nov 1;129(11):4769-4785. doi: 10.1172/JCI128699 | 2019 | HIV | Faruk Sinangil | Rouphael et al | | |
| Giuseppe Pantaleo, Holly Janes, Shelly Karuna, Shannon Grant, Laissa Ouedraogo, Mary Allen, Georgia D. Tomaras, Nicole Frahm, David C. Montefiori, Guido Ferrari, Song Ding, Carter Lee , Merlin L. Robb, Mariano Esteban, Ralf Wagner, Pierre Alexandre-Bart, Nils Rettby, M. Juliana McElrath, Peter B. Gilbert, James Kublin, and Lawrence Corey and the NIAID HIV Vaccine Trials Network | Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial | The Lancet HIV. 2019; 6(11): PE737-E749. doi: 10.1016/S2352-3018(19)30262-0 | 2019 | HIV | Carter Lee | Pantaleo et al | | |
| Gray GE, Huang Y, Grunenber N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F , Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L. | Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. | Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880. | 2019 | HIV | Faruk Sinangil, Carter Lee | Gray et al | | |
| Mesa KA, Yu B, Wrin T, Petropoulos CJ, Pogson GH, Alexander DL, Perez G, O'Rourke SM, Sinangil F , Robinson J, Conant MA, Berman PW. | Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens. | PLoS One. 2019 Apr 10;14(4):e0213409. doi: 10.1371/journal.pone.0213409. eCollection 2019 | 2019 | HIV | Faruk Sinangil | Mesa et al | | |

| | | | | | | | | |
|---|---|---|------|-----|---|-----------------------|--|--|
| Akpirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F , de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N; RV305 Study Group. | Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. | PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018. | 2018 | HIV | Faruk Sinangil | Akpirat et al | | |
| Balasubramanian P, Williams C, Shapiro MB, Sinangil F , Higgins K , Nádas A, Totrov M, Kong XP, Fiore-Gartland AJ, Haigwood NL, Zolla-Pazner S, Hioe CE. | Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. | Sci Rep. 2018 Jan 11;8(1):542. doi: 10.1038/s41598-017-18863-0. | 2018 | HIV | Faruk Sinangil, Keith Higgins | Balasubramanian et al | | |
| Karnasuta Chitraporn, Akpirat Siriwat, Madnote Sirinan, Savadsuk Hathairat, Puangkaew Jiraporn, Rittiroongrad Surawach, Rerks-Ngarm Supachai, Nitayaphan Sorachai, Pitisuttithum Punnee, Kaewkungwal Jaranit, Tartaglia James, Sinangil Faruk , Francis Donald P. , Robb Merlin L., de Souza Mark S., Michael Nelson L., Excler Jean-Louis, Kim Jerome H., O'Connell Robert J., and Karasavvas Nicos | Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens | AIDS Research and Human Retroviruses. May 2017, 33(5): 410-423. doi:10.1089/aid.2016.0204 | 2016 | HIV | Faruk Sinangil, Don Francis | Karnasuta et al | | |
| Peter B. Gilbert, Jean-Louis Excler, Georgia D. Tomaras, Lindsay N. Carpp, Barton F. Haynes, Hua-Xin Liao, David C. Montefiori, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Gustavo H. Kijak, Sodsai Tovanabutra, Donald P. Francis, Carter Lee, Faruk Sinangil, Phillip W. Berman, Nakorn Prensri, Prayura Kunasol, Robert J. O'Connell, Nelson L. Michael, Merlin L. Robb, Rhoda Morrow, Lawrence Corey, Jerome H. Kim | Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women | PLOS ONE 12(5): e0176428. https://doi.org/10.1371/journal.pone.0176428 | 2017 | HIV | Don Francis, Carter Lee, and Faruk Sinangil | Gilbert et al | | |
| Supachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, Sorachai Nitayaphan, Jaranit Kaewkungwal, Nakorn Prensri, Prayura Kunasol, Nicos Karasavvas. Alexandra Schuetz, Viseth Ngauy, Faruk Sinangil , Peter Dawson, Allan C. deCamp, Sanjay Phogat, Sanjay Garunathan, James Tartaglia, Carlos DiazGranados, Silvia Ratto-Kim, Poonam Pegu, Michael Eller, Chitraporn Karnasuat, David C. Montefiori, Sheetal Sawant, Nathan Vandergrift, Saintedym Wills, Georgia D. Tomaras, Merlin L. Robb, Nelson L. Michael, Jerome H. Kim, Sandhya Vasan, Robert J. O'Connell for the RV305 Study Team | Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial | J Infect Dis. 2017 Feb 21. doi: 10.1093/infdis/jix099. | 2017 | HIV | Faruk Sinangil | Rerks-Ngarm et al | | |

| | | | | | | | | |
|---|--|---|-------------|------------|--------------------------------------|------------------------------|--|--|
| <p>Preetha Balasubramanian, Rajnish Kumar, Constance Williams, Vincenza Itri, Shixia Wang, Shan Lu, Ann J. Hessel, Nancy L. Haigwood, Faruk Sinangil, Keith W. Higgins, Lily Liu, Liuzhe Li, Phillipe Nyambi, Mirosław K. Gorny, Maxim Totrov, Arthur Nadas, Xiang-Peng Kong, Susan Zolla-Pazner, Catarina E. Hioe</p> | <p>Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination</p> | <p>Vaccine. 2017 Feb 6. pii: S0264-410X(17)30089-0. doi: 10.1016/j.vaccine.2016.11.107.</p> | <p>2017</p> | <p>HIV</p> | <p>Faruk Sinangil, Keith Higgins</p> | <p>Balasubramanian et al</p> | | |
| <p>David Easterhoff , M. Anthony Moody, Daniela Fera, Hao Cheng, Margaret Ackerman, Kevin Wiehe, Kevin O. Saunders, Justin Pollara, Nathan Vandergrift, Rob Parks, Jerome Kim, Nelson L. Michael, Robert J. O'Connell, Jean-Louis Excler, Merlin L. Robb, Sandhya Vasan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, James Tartaglia, Sanjay Phogat, Thomas B. Kepler, S. Munir Alam, Hua-Xin Liao, Guido Ferrari, Michael S. Seaman, David C. Montefiori, Georgia D. Tomaras, Stephen C. Harrison, Barton F. Haynes</p> | <p>Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial</p> | <p>PLoS Pathog 13(2): e1006182. doi:10.1371/journal.ppat.1006182</p> | <p>2017</p> | <p>HIV</p> | <p>Faruk Sinangil</p> | <p>Easterhoff et al</p> | | |
| <p>Dr. Chitraporn Karnasuta, Dr. Siriwat Akapirat, Ms. Sirinan Madnote, Ms. Hathairat Savadsuk, Ms. Jiraporn Puangkaew, Mr. Surawach Rittiroongrad, Dr. Supachai Rerks-ngarm, Dr. Sorachai Nitayaphan, Prof. Punnee Pitisuttithum, Dr. Jaranit Kaewkungwal, Dr. Jim Tartaglia, Dr. Faruk Sinangil, Dr. Donald P Francis, Dr. Merlin Robb, Dr. Mark de Souza, Dr. Nelson L. Michael, Dr. Jean-Louis Excler, Dr. Jerome H Kim, Dr. Robert J O'Connell, and Dr. Nicos Karasavvas</p> | <p>Comparison of Antibody Responses Induced by RV144, VAX003 and VAX004 Vaccination Regimens.</p> | <p>AIDS Res Hum Retroviruses. 2017 May;33(5):410-423. doi: 10.1089/AID.2016.0204</p> | <p>2016</p> | <p>HIV</p> | <p>Faruk Sinangil, Don Francis</p> | <p>Karnasuta et al</p> | | |

| | | | | | | | | |
|--|--|--|-------------|------------|--|-------------------------|--|--|
| <p>Kan Luo, Hua-Xin Liao, Ruijun Zhang, David Easterhoff, Kevin Wiehe, Thaddeus C. Gurley, Lawrence C. Armand, Ashley A. Allen, Tarra A. Von Holle, Dawn J. Marshall, John F. Whitesides, Jamie Pritchett, Andrew Foulger, Giovanna Hernandez, Robert Parks, Krissey E. Lloyd, Christina Stolarchuk, Sheetal Sawant, Jessica Peel, Nicole L. Yates, Erika Dunford, Sabrina Arora, Amy Wang, Cindy M. Bowman, Laura L. Sutherland, Richard M. Scarce, Shi-Mao Xia, Mattia Bonsignori, Justin Pollara, R. Whitney Edwards, Sampa Santra, Norman L. Letvin, James Tartaglia, Donald Francis, Faruk Sinangil, Carter Lee, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnee Pitisuttithum, Supachai Rerk-ngarm, Nelson L. Michael, Jerome H. Kim, S. Munir Alam, Nathan A. Vandergrift, Guido Ferrari, David C. Montefiori, Georgia D. Tomaras, Barton F. Haynes, and M. Anthony Moody</p> | <p>Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.</p> | <p>JCI Insight. 2016 Dec 8;1(20):e88522. DOI: 10.1172/jci.insight.88522</p> | <p>2016</p> | <p>HIV</p> | <p>Faruk Sinangil, Don Francis, Carter Lee</p> | <p>Luo et al</p> | | |
| <p>Alison E. Mahan, Madeleine F. Jennewein, Todd Suscovich, Kendall Dionne, Jacquelynne Tedesco, Amy W. Chung, Hendrik Streeck, Maria Pau, Hanneke Schuitemaker, Don Francis, Patricia Fast, Dagna Laufer, Bruce D. Walker, Lindsey Baden, Dan H. Barouch, Galit Alter</p> | <p>Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination</p> | <p>PLoS Pathog 12(3): e1005456. doi: 10.1371/journal.ppat.1005456</p> | <p>2016</p> | <p>HIV</p> | <p>Don Francis</p> | <p>Mahan et al</p> | | |
| <p>Nicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, Sirinan Madnote, Dutsadee Inthawong, Somsak Chantakulkij, Surawach Rittiroongrad, Sorachai Nitayaphan, Punnee Pitisuttithum, Prasert Thongcharoen, Vinai Siriyanon, Charla A. Andrews, Susan W. Barnett, James Tartaglia, Faruk Sinangil, Donald P. Francis, Merlin L. Robb, Nelson L. Michael, Viseth Ngauy, Mark S. de Souza, Robert M. Paris, Jean-Louis Excler, Jerome H. Kim, and Robert J. O'Connell, for the MOPH-TAVEG Collaboration</p> | <p>IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.</p> | <p>AIDS Research and Human Retroviruses. 2015;31(11):1178-1186. doi:10.1089/aid.2015.0034.</p> | <p>2015</p> | <p>HIV</p> | <p>Faruk Sinangil, Don Francis</p> | <p>Karasavvas et al</p> | | |

| | | | | | | | | |
|---|--|--|------|----------|----------------|-------------|--|--|
| Kevin Wiehe, David Easterhoff, Kan Luo, Nathan I. Nicely, Todd Bradley, Frederick H. Jaeger, S. Moses Dennison, Ruijun Zhang, Krissey E. Lloyd, Christina Stolarchuk, Robert Parks, Laura L. Sutherland, Richard M. Scarce, Lynn Morris, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Faruk Sinangil , Sanjay Phogat, Nelson L. Michael, Jerome H. Kim, Garnett Kelsoe, David C. Montefiori, Georgia D. Tomaras, Mattia Bonsignori, Sampa Santra, Thomas B. Kepler, S. Munir Alam, M. Anthony Moody, Hua-Xin Liao, and Barton F. Haynes | Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. | Immunity. 2014;41(6):909-918. doi:10.1016/j.immuni.2014.11.014. | 2014 | HIV | Faruk Sinangil | Wiehe et al | | |
| Nicola Dell, Ian Francis , Haynes Sheppard, Raiva Simbi, and Gaetano Borriello. | Field evaluation of a camera-based mobile health system in low-resource settings. | In Proceedings of the 16th international conference on Human-computer interaction with mobile devices & services (MobileHCI '14). ACM, New York, NY, USA, 33-42. DOI=10.1145/2628363.2628366 | 2014 | mHealth | Ian Francis | Dell et al | | |
| Amy W. Chung, Musie Ghebremichael, Hannah Robinson, Eric Brown ² , Ickwon Choi, Sophie Lane, Anne-Sophie Dugast, Matthew K. Schoen, Morgane Rolland, Todd J. Suscovich, Alison E. Mahan, Larry Liao, Hendrik Streeck, Charla Andrews, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Mark S. de Souza, Jaranit Kaewkungwal, Punnee Pitisuttithum, Donald Francis , Nelson L. Michael, Jerome H. Kim, Chris Bailey-Kellogg, Margaret E. Ackerman and Galit Alter | Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines | Sci Transl Med 19 March 2014: (6/ 228: 228-38) Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007736 | 2014 | HIV | Don Francis | Chung et al | | |
| Arita I, Francis D , Saijo M. | Chapter 21. Variola Viruses. In: Manual of Security Sensitive Microbes and Toxins. | Ed. Don Liu. CRC Press 2014. | 2014 | Smallpox | Don Francis | Arita et al | | |
| Arita I, Francis D | Is it time to destroy the smallpox virus? | Science 29 August 2014: 1010. DOI:10.1126/science.345.6200.1010-a | 2014 | Smallpox | Don Francis | Arita et al | | |

| | | | | | | | | |
|--|--|--|------|---------|---|----------------|--|--|
| Francis DP, Du Y-P and Precioso AR | Global Vaccine Supply - the increasing role of manufacturers from middle income countries | Vaccine 32: 5259-5265; 2014 | 2014 | General | Don Francis | Francis et al | | |
| Oksana Penezina, Neil X. Krueger, Isaac R. Rodriguez-Chavez, Michael P. Busch, John Hural, Jerome H. Kim, Robert J. O'Connell, Eric Hunter, Said Aboud, Keith Higgins , Victor Kovalenko, David Clapham, David Crane, Andrew E. Levin, and the HIV Selectest Study Group | Performance of a Redesign HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants | Clin Vaccine Immunol March 2014 vol. 21 no. 3 391-398 | 2014 | HIV | Keith Higgins | Penezina et al | | |
| Nicole L. Yates, Hua-Xin Liao, Youyi Fong, Allan deCamp, Nathan A. Vandergrift, William T. Williams, S. Munir Alam, Guido Ferrari, Zhi-yong Yang ⁴ , Kelly E. Seaton, Phillip W. Berman, Michael D. Alpert, David T. Evans, Robert J. O'Connell, Donald Francis , Faruk Sinangil , Carter Lee , Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Abraham Pinter, Susan Zolla-Pazner, Peter B. Gilbert, Gary J. Nabel, Nelson L. Michael, Jerome H. Kim, David C. Montefiori ¹ , Barton F. Haynes and Georgia D. Tomaras | Vaccine-Induced Env V1/V2 IgG3 Correlate with Lower HIV-Infection Risk and Declines Soon After Vaccination | Sci Transl Med 19 March 2014: Vol. 6, Issue 228, p. 228ra39 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007730 | 2014 | HIV | Don Francis, Carter Lee, and Faruk Sinangil | Yates et al | | |
| Dubin C, Francis DP | Closing the circle: a thirty-year retrospective on the AIDS/blood epidemic. | Transfusion, 2013, Vol 53 (9), DOI: 10.1111/trf.12374 | 2013 | HIV | Don Francis | Dubin et al | | |
| Raphael Gottardo, Robert T. Bailer, Bette T. Korber, S. Gnanakaran, Joshua Phillips, Xiaoying Shen, Georgia D. Tomaras, Ellen Turk, Gregory Imholte, Larry Eckler, Holger Wenschuh, Johannes Zerweck, Kelli Greene, Hongmei Gao, Phillip W. Berman, Donald Francis , Faruk Sinangil , Carter Lee , Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Targalia, Merlin L. Robb, Nelson L. Michael, Jerome H. Kim, Susan Zolla-Pazner, Barton F. Haynes, John R. Mascola, Steve Self, Peter Gilbert, David C. Montefiori | Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial | PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013. | 2013 | HIV | Don Francis, Carter Lee, and Faruk Sinangil | Gottardo et al | | |

| | | | | | | | | |
|---|---|---|------|-----|----------------|----------------|--|--|
| Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL Jr, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F , Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, Harrison SC, Haynes BF | Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. | J Virol. 2013 Feb;87(3):1554-68. doi: 10.1128/JVI.00718-12. Epub 2012 Nov 21. | 2013 | HIV | Faruk Sinangil | Alam et al | | |
| Hua-Xin Liao, Mattia Bonsignori, S. Munir Alam, Jason S. McLellan, Georgia D. Tomaras, M. Anthony Moody, Daniel M. Kozink, Kwan-Ki Hwang, Xi Chen, Chun-Yen Tsao, Pinghuang Liu, Xiaozhi Lu, Robert J. Parks, David C. Montefiori, Guido Ferrari, Justin Pollara, Mangala Rao, Kristina K. Peachman, Sampa Santra, Norman L. Letvin, Nicos Karasavvas, Zhi-Yong Yang, Kaifan Dai, Marie Pancera, Jason Gorman, Kevin Wiehe, Nathan I. Nicely, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Faruk Sinangil , Jerome H. Kim, Nelson L. Michael, Thomas B. Kepler, Peter D. Kwong, John R. Mascola, Gary J. Nabel, Abraham Pinter, Susan Zolla-Pazner, Barton F. Haynes | Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Immunity - 24 January 2013 (Vol. 38, Issue 1, pp. 176-186). doi: 10.1016/j.immuni.2012.11.011 | 2013 | HIV | Faruk Sinangil | Liao et al | | |
| O'Rourke SM1, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, To B, Sinangil F , Limoli K, Wrin T, Berman PW. | Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. | J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29. | 2012 | HIV | Faruk Sinangil | O'Rourke et al | | |
| Francis, Donald P. | Deadly AIDS policy failure by the highest levels of the US government: a personal look back 30 years later for lessons to respond better to future epidemics. | Journal of Public Health Policy (2012) 33, 290–300. doi:10.1057/jphp.2012.14 | 2012 | HIV | Don Francis | Francis | | |

| | | | | | | | | |
|--|--|--|------|---------|---|------------------|--|--|
| Francis, Donald P. | Protecting the public's health: remove the political constraints that hamper the Centers for Disease Control and Prevention. | AIDS. 2012 Jun 1;26(9):1175-6. doi:10.1097/QAD.0b013e32835392dd | 2012 | General | Don Francis | Francis | | |
| Karasavvas, Nicos; Erik Billings, Mangala Rao, Constance Williams, Susan Zolla-Pazner, Robert T. Bailer, Richard A. Koup, Sirinan Madnote, Duangnapa Arworn, Xiaoying Shen, Georgia D. Tomaras, Jeffrey R. Currier, Mike Jiang, Craig Magaret, Charla Andrews, Raphael Gottardo, Peter Gilbert, Timothy J. Cardozo, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Robert Paris, Kelli Greene, Hongmei Gao, Sanjay Gurunathan, Jim Tartaglia, Faruk Sinangil , Bette T. Korber, David C. Montefiori, John R. Mascola, Merlin L. Robb, Barton F. Haynes, Viseth Ngauy, Nelson L. Michael, Jerome H. Kim, and Mark S. de Souza, for the MOPH TAVEG Collaboration | The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120 | AIDS Research and Human Retroviruses. November 2012, 28(11): 1444-1457. doi: 10.1089/aid.2012.0103 | 2012 | HIV | Faruk Sinangil | Karasavvas et al | | |
| Mahoney, R.T.; D.P. Francis , N.M. Frazatti-Gallina, A.R. Precioso, I. Raw, P. Watler, P. Whitehead, S.S. Whitehead | Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil. | Vaccine, Volume 30, Issue 32, 6 July 2012, Pages 4892-4896, ISSN 0264-410X, 10.1016/j.vaccine.2012.02.064. | 2012 | Dengue | Don Francis | Mahoney et al | | |
| Montefiori, David C.; Chitraporn Karnasuta, Ying Huang, Hasan Ahmed, Peter Gilbert, Mark S. de Souza, Robert McLinden, Sodsai Tovanabutra, Agnes Laurence-Chenine, Eric Sanders-Buell, M. Anthony Moody, Mattia Bonsignori, Christina Ochsenbauer, John Kappes, Haili Tang, Kelli Greene, Hongmei Gao, Celia C. LaBranche, Charla Andrews, Victoria R. Polonis, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Steve G. Self, Phillip W. Berman, Donald Francis , Faruk Sinangil , Carter Lee , Jim Tartaglia, Merlin L. Robb, Barton F. Haynes, Nelson L. Michael, and Jerome H. Kim. | Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. | J Infect Dis. (2012) 206(3): 431-441. doi:10.1093/infdis/jis367 | 2012 | HIV | Don Francis, Carter Lee, and Faruk Sinangil | Montefiori et al | | |

| | | | | | | | | |
|--|--|--|------|-----|----------------|-------------------|--|--|
| O'Rourke SM, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, To B, Sinangil F , Limoli K, Wrin T, Berman PW. | Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies. | J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29. | 2012 | HIV | Faruk Sinangil | O'Rourke et al | | |
| Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Prem Sri N, Namwat C, Bowonwatanuwong C, Li SS, Kaewkungkal J, Trichavaroj R, Churikanont N, de Souza MS, Andrews C, Francis D , Adams E, Flores J, Gurunathan S, Tartaglia J, O'Connell RJ, Eamsila C, Nitayaphan S, Ngauy V, Thongcharoen P, Kunasol P, Michael NL, Robb ML, Gilbert PB, Kim JH | Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. | J Infect Dis. first published online July 26, 2012 doi:10.1093/infdis/jis478 | 2012 | HIV | Don Francis | Rerks-Ngarm et al | | |
| Robb MD, Merlin L; Supachai Rerks-Ngarm MD, Sorachai Nitayaphan MD, Prof Punnee Pitisuttithum MD, Jaranit Kaewkungwal PhD, Prayura Kunasol MD, Chirasak Khamboonruang MD, Prof Prasert Thongcharoen MD, Patricia Morgan MS, Michael Benenson MD, Robert M Paris MD, Joseph Chiu MD, Elizabeth Adams MD, Donald Francis MD , Sanjay Gurunathan MD, Jim Tartaglia PhD, Peter Gilbert PhD, Don Stablein PhD, Nelson L Michael MD, Dr Jerome H Kim MD | Risk behavior and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | The Lancet Infectious Diseases, Volume 12, Issue 7, Pages 531 - 537, July 2012. DOI: 10.1016/S1473-3099(12)70088-9 | 2012 | HIV | Don Francis | Robb et al | | |
| S. Munir Alam, Hua-Xin Liao, Georgia D. Tomaras, Mattia Bonsignori, Chun-Yen Tsao, Kwan-Ki Hwang, Haiyan Chen, Krissey E. Lloyd, Cindy Bowman, Laura Sutherland, Thomas L. Jeffries Jr., Daniel M. Kozink, Shelley Stewart, Kara Anasti, Frederick H. Jaeger, Robert Parks, Nicole L. Yates, R. Glenn Overman, Faruk Sinangil , Phillip W. Berman, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Nicos Karasavva, Supachai Rerks-Ngarm, Jerome H. Kim, Nelson L. Michael, Susan Zolla-Pazner, Sampa Santra, Norman L. Letvin, Stephen C. Harrison, and Barton F. Haynes | Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen is Enhanced by a gp120 N-terminal Deletion | J. Virol. February 2013 87:3 1554-1568; published ahead of print 21 November 2012, doi:10.1128/JVI.00718-12 | 2012 | HIV | Faruk Sinangil | Alam et al | | |

| | | | | | | | | |
|---|---|--|------|-----------|----------------|------------------|--|--|
| Stephenson, Kathryn E.; John Hural, Susan P. Buchbinder, Faruk Sinangil , and Dan H. Barouch. | Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials. | J Infect Dis. (2012) 205(12): 1806-1810 first published online April 5, 2012 doi:10.1093/infdis/jis285 | 2012 | HIV | Faruk Sinangil | Stephenson et al | | |
| Arita, Isao and Donald P. Francis . | Safe landing for global polio eradication: A Perspective. | Vaccine. 29 (2011) 8827-34. doi:10.1016/j.vaccine.2011.09.059 | 2011 | Polio | Don Francis | Arita et al | | |
| Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F , de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J. | International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. | Vaccine. 2011 Jul 18;29 (32):5203-9. Epub 2011 May 25. doi:10.1016/j.vaccine.2011.05.025 | 2011 | HIV | Faruk Sinangil | Barouch et al | | |
| Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F , Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. | Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. | J Virol. 2011 Oct;85(19):9998-10009. Epub 2011 Jul 27. doi:10.1128/JVI.05045-11 | 2011 | HIV | Faruk Sinangil | Bonsignori et al | | |
| Francis, Donald P. and Gary Grohmann | WHO Influenza vaccine technology transfer initiative: Role and activities of the Technical Advisory Group. | Vaccine 295 (2011) A45-A47. doi:10.1016/j.vaccine.2011.02.078 | 2011 | Influenza | Don Francis | Francis et al | | |
| Mahoney R, Chocarro L, Southern J, Francis DP , Vose J, Margolis H. | Dengue vaccines regulatory pathways: A report on two meetings with regulators of developing countries. | PLoS Med 8(2): e1000418. Published February 22, 2011. doi:10.1371/journal.pmed.1000418. | 2011 | Dengue | Don Francis | Mahoney et al | | |

| | | | | | | | | |
|--|---|---|------|---------|----------------|--------------------|--|--|
| Bonsignori M1, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F , Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. | J Virol. 2011 Oct;85(19):9998-10009. doi: 10.1128/JVI.05045-11. Epub 2011 Jul 27. | 2011 | HIV | Faruk Sinangil | Bonsignori et al | | |
| Barouch DH1, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F , de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amorukul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J. | International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. | Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25. | 2011 | HIV | Faruk Sinangil | Barouch et al | | |
| Pérez-Losada M, Jobes DV, Sinangil F , Crandall KA, Arenas M, Posada D, Berman PW. | Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand. | PLoS One. 2011 Mar 10;6(3):e16902. doi:10.1371/journal.pone.0016902 | 2011 | HIV | Faruk Sinangil | Perez-Losada et al | | |
| Pitisuttihum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayapan S, Kaewkungwal J, Benenson M, Morgan P, O'Connell R, Berenberg J, Gurunathan S, Francis DP , Paris R, Chiu J, Stablein D, Michael NL, Excler JL, Rob M, Kim J. Jerome H. Kim. | Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. | PLoS Vol 6, Issue 12, e27837, December 2011. doi:10.1371/journal.pone.0027837 | 2011 | HIV | Don Francis | Pitisuttihum et al | | |
| The Ministry of Public Health – Thai AIDS Vaccine Evaluation Group (MOPH-TAVEG). | Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). | Vaccine 29 (2011) 4285-4292. doi:10.1016/j.vaccine.2011.03.014 | 2011 | HIV | Don Francis | MOPH-TAVEG | | |
| Francis DP. | Successes and failures: Worldwide vaccine development and application. | Biologicals. 2010 Sep;38(5):523-8. Epub 2010 Aug 4. Review. doi:10.1016/j.biologicals.2010.06.003 | 2010 | General | Don Francis | Francis | | |

| | | | | | | | | |
|---|---|--|------|--------|----------------|--------------------|--|--|
| Francis, Don, Douglas D, Mahoney R. | The manufacture and supply of dengue vaccine. | Occasional Paper, Pediatric Dengue Vaccine Initiative, International Vaccine Institute, December 2010. | 2010 | Dengue | Don Francis | Francis et al | | |
| Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, Decamp A, Giganti M, Berman PW, Self SG, and Montefiori DC. | Magnitude and breadth of a non-protective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. | J Infect Dis 202 (4): 595-605 (2010). doi: 10.1086/654816 | 2010 | HIV | Faruk Sinangil | Gilbert et al | | |
| O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, Sinangil F, Berman PW. | Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. | J Virol. 2010 Nov;84(21):11200-9. doi:10.1128/JVI.00790-10 | 2010 | HIV | Faruk Sinangil | O'Rourke et al | | |
| Perez-Losada M, Jobes DV, Sinangil F, , and Crandall KA, Posada D, and Berman PW. | Phylogenetics of HIV-1 from a phase-III AIDS vaccine trial in North America. | Mol Biol Evol 27(2):417-25 (2010). doi: 10.1093/molbev/msp254 | 2010 | HIV | Faruk Sinangil | Perez-Losada et al | | |
| Smith DH, Winters-Digiacinto P, Mitiku M, O'Rourke S, Sinangil F, Wrin T, Montefiori DC, Berman PW. | Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. | PLoS One 5(8): e12076 (2010). Doi:1371/journal.pone.0012076 | 2010 | HIV | Faruk Sinangil | Smith et al | | |
| O'Rourke SM, Schweighardt B, Scott W, Wrin T, Fonseca D, Sinangil F, and Berman PW. | Novel ring structure in the gp41 trimer of human deficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. | J Virol. 83(15):7728-38 (2009). doi:10.1128/JVI.00688-09 | 2009 | HIV | Faruk Sinangil | O'Rourke et al | | |
| Perez-Losada M, Posada D, Jobes DV, Sinangil F, Berman PW, and Crandall KA. | Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. | Retrovirology 6:67 (2009). doi:10.1186/1742-4690-6-67 | 2009 | HIV | Faruk Sinangil | Perez-Losada et al | | |
| Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Prensri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators. | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. | N Engl J Med. 2009 Dec 3;361(23):2209-20. Epub 2009 Oct 20. doi:10.1056/NEJMoa0908492 | 2009 | HIV | Don Francis | Rerks-Ngarm et al | | |

| | | | | | | | | |
|--|---|--|------|-----|----------------|---------------------|--|--|
| Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, van Griensven F, Phonrat B, Martin M, Vimutsunthorn E, Sangkum U, Kitayaporn D, Tappero JW, Heyward W, Francis D. | Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. | J Med Assoc Thai. 2007 Nov;90(11):2442-8. | 2007 | HIV | Don Francis | Pitisuttithum et al | | |
| Jobes DV, Daoust M, Nguyen V, Padua A, Michele S, Lock MD, Chen A, Sinangil F , and Berman PW | High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV-1 infections from a Phase 3 vaccine efficacy trial. | AIDS Res Hum Retroviruses 22 (10):1014-21 (2006). doi:10.1089/aid.2006.22.1014 | 2006 | HIV | Faruk Sinangil | Jobes et al | | |
| Jobes DV, Daoust M, Nguyen V, Padua A, Sinangil F , Perez-Losada M, Crandall KA, Oliphant T, Posada D, Rambaut A, Fuchs J, Berman PW. | Longitudinal population analysis of dual infection with recombination in two strains of HIV-1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial. | AIDS Res Hum Retroviruses 22 (10): 968-78 (2006). doi: 10.1089/aid.2006.22.968 | 2006 | HIV | Faruk Sinangil | Jobes et al | | |